PT2368565E - Enriquecimento de lipoproteínas pré-beta de alta densidade - Google Patents

Enriquecimento de lipoproteínas pré-beta de alta densidade Download PDF

Info

Publication number
PT2368565E
PT2368565E PT101853810T PT10185381T PT2368565E PT 2368565 E PT2368565 E PT 2368565E PT 101853810 T PT101853810 T PT 101853810T PT 10185381 T PT10185381 T PT 10185381T PT 2368565 E PT2368565 E PT 2368565E
Authority
PT
Portugal
Prior art keywords
enrichment
high density
density lipoproteins
beta high
beta
Prior art date
Application number
PT101853810T
Other languages
English (en)
Inventor
Marc Bellotti
Hassibullah Akeefe
Bryan H Brewer
Adam Paul Conner
Timothy Jon Perlman
Original Assignee
Hdl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hdl Therapeutics Inc filed Critical Hdl Therapeutics Inc
Publication of PT2368565E publication Critical patent/PT2368565E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
PT101853810T 2003-07-03 2004-03-08 Enriquecimento de lipoproteínas pré-beta de alta densidade PT2368565E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48469003P 2003-07-03 2003-07-03

Publications (1)

Publication Number Publication Date
PT2368565E true PT2368565E (pt) 2015-10-19

Family

ID=34115319

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04718501T PT1641421T (pt) 2003-07-03 2004-03-08 Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
PT101853810T PT2368565E (pt) 2003-07-03 2004-03-08 Enriquecimento de lipoproteínas pré-beta de alta densidade

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT04718501T PT1641421T (pt) 2003-07-03 2004-03-08 Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido

Country Status (9)

Country Link
US (5) US7375191B2 (pt)
EP (2) EP1641421B1 (pt)
JP (1) JP2007527387A (pt)
AU (1) AU2004260632A1 (pt)
CA (1) CA2531227A1 (pt)
DK (2) DK1641421T3 (pt)
ES (2) ES2547547T3 (pt)
PT (2) PT1641421T (pt)
WO (1) WO2005011620A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641421B1 (en) * 2003-07-03 2018-12-26 HDL Therapeutics, Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
EP1685852A1 (en) * 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
PT1917029E (pt) * 2005-07-27 2013-03-13 Lilly Co Eli Um método de tratamento de células cancerígenas para criar uma célula cancerígena modificada que provoca uma resposta imunogénica
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
ITMO20060097A1 (it) * 2006-03-24 2007-09-25 Giuseppe Zucca Dispositivo e metodo per la diluizione e l'allestimento di farmaci antiblastici
US8785382B2 (en) 2006-04-03 2014-07-22 Abbott Cardiovascular Systems Inc. Lipid therapy
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
EP2488228A4 (en) * 2009-10-18 2018-03-21 Glycorex AB Method and product for blood treatment and purification
ES2532006T3 (es) * 2009-11-20 2015-03-23 Pharnext Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth
CN107337728B (zh) * 2011-02-07 2023-05-23 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
US10624924B2 (en) * 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
AU2015201496B2 (en) 2014-06-03 2019-10-31 Grifols Worldwide Operations Limited Use of plasmapheresis to treat blood pressure disorders
AU2018210980A1 (en) * 2017-01-23 2019-08-08 Hdl Therapeutics, Inc. Methods for treating cholesterol-related diseases
EP3589272A4 (en) * 2017-03-01 2020-11-25 HDL Therapeutics, Inc. METHODS FOR PREVENTING PROPHYLAXIS, SLOWING EVOLUTION OR TREATING ALZHEIMER'S DISEASE
WO2019104237A1 (en) * 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (en) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. PROCESSES FOR THE STORAGE AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEINS EXTRACTED FROM HUMAN PLASMA
AU2019264938A1 (en) * 2018-05-11 2020-12-03 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647624A (en) 1969-07-24 1972-03-07 Wisconsin Alumni Res Found Treatment of blood with oleaginous substance
US3989466A (en) 1973-08-13 1976-11-02 Pan Samuel C Liquid-liquid extraction apparatus including fibrous strand packing
JPS5328989B2 (pt) 1974-05-27 1978-08-17
US3983028A (en) * 1974-07-01 1976-09-28 Standard Oil Company (Indiana) Process for recovering upgraded products from coal
US3958939A (en) 1975-01-08 1976-05-25 Coulter Electronics, Inc. Method for clarification of lipemic serum
DE2501376A1 (de) 1975-01-15 1976-07-22 Metallgesellschaft Ag Verfahren zur entfernung von mono- und diphenolen und dergleichen aus abwaessern
US4258010A (en) 1975-11-19 1981-03-24 Eszakmagyarorszagi Vegyimu_ vek Solvent extraction apparatus
JPS5272379A (en) 1975-12-15 1977-06-16 Toray Ind Inc Separation of fluid
US4103685A (en) 1976-01-05 1978-08-01 Lupien Paul J Method and apparatus for extravascular treatment of blood
DE2710241A1 (de) 1976-03-11 1977-09-22 Krebs & Co Ag Verfahren zum vermengen und trennen von zwei nicht mischbaren fluessigkeiten
JPS5549791Y2 (pt) 1976-04-21 1980-11-20
US4671909A (en) 1978-09-21 1987-06-09 Torobin Leonard B Method for making hollow porous microspheres
JPS55127104A (en) * 1979-03-23 1980-10-01 Seikouen Hosono Shinriyoushiyo Method for continuous extraction of minor component and device therefor
FR2455743A1 (fr) 1979-05-02 1980-11-28 Goella Laboratoires Procede et dispositif pour le dosage des lipoproteines seriques
US4234317A (en) 1979-05-24 1980-11-18 Analytical Products, Inc. Apparatus and method for fractionation of lipoproteins
DE2944138A1 (de) * 1979-11-02 1981-06-11 Technicon Gmbh, 6368 Bad Vilbel Verfahren und vorrichtung zur durchfuehrung von analysen in automatischen analysensystemen unter abtrennung von niederschlaegen
DE2949907A1 (de) * 1979-12-12 1981-06-19 Hoechst Ag, 6230 Frankfurt Fluorpolymere mit schalenmodifizierten teilchen und verfahren zu deren herstellung
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
EP0036283A3 (en) * 1980-03-19 1982-03-31 DAVY MCKEE (MINERALS & METALS) LIMITED Method and apparatus for liquid-liquid extraction
US4311586A (en) * 1980-04-22 1982-01-19 Tracor, Inc. Solvent mixing in HPLC using low pressure solvent metering pumps
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
DE3118072A1 (de) * 1981-05-07 1982-11-25 Claus-Christian Dr.Rer.Nat. Dr.Med. 6901 Wilhelmsfeld Heuck Verfahren zur trennung von lipophilen bestandteilen aus waessrigen kolloid-loesungen zu praeparativen zwecken und/oder zum nachweis eines analyts in waessriger phase
DE3280188D1 (de) 1981-09-10 1990-07-19 Braun Melsungen Ag Vorrichtung zur selektiven extrakorporalen praezipation von low density lipoprotenen aus vollserum oder plasma.
US4435289A (en) 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
JPS58155865A (ja) 1982-03-12 1983-09-16 株式会社クラレ 血漿処理用中空糸膜
DE3213390A1 (de) * 1982-04-10 1983-10-20 Dieter 3000 Hannover Biela Vorrichtung zur bilanzierung des fluessigkeitsaustausches bei haemofiltrationen
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
EP0101066B1 (en) 1982-08-14 1988-12-21 Gustav E. Dr. Phil. Utzinger Liquid-spraying system
US4463988A (en) 1982-09-07 1984-08-07 Cities Service Co. Horizontal heated plane process
SU1204224A1 (ru) * 1982-12-30 1986-01-15 Казанский Ордена Трудового Красного Знамени Химико-Технологический Институт Им.С.М.Кирова Центробежный экстрактор
US4540401A (en) 1983-02-22 1985-09-10 Applied Immune Sciences, Inc. In vivo therapeutic apheresis using lipid vesicles
US4643718A (en) 1983-02-22 1987-02-17 Applied Immunesciences, Inc. Therapeutic apheresis
DE3310263A1 (de) * 1983-03-22 1984-09-27 Fresenius AG, 6380 Bad Homburg Verfahren zur entfernung von lipophilen stoffen aus waessrigen loesungen sowie vorrichtung zur durchfuehrung des verfahrens
DE3310727A1 (de) 1983-03-24 1984-10-04 B. Braun Melsungen Ag, 3508 Melsungen Verfahren und vorrichtung zur selektiven, extrakorporalen abtrennung pathologischer und/oder toxischer blutbestandteile
SU1116396A1 (ru) * 1983-05-23 1984-09-30 2-Й Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова Способ удалени холестерина из крови
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4668398A (en) 1983-07-21 1987-05-26 Colgate-Palmolive Company Continuous extraction apparatus and process
US4615886A (en) 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
GB8330094D0 (en) * 1983-11-11 1983-12-21 Ici Plc Diphenyl compounds
JPS60231613A (ja) 1984-04-28 1985-11-18 Terumo Corp Ｔ細胞とｂ細胞の分離方法およびその分離材ならびにその分離装置
DE3422407A1 (de) 1984-06-16 1986-03-06 B. Braun Melsungen Ag, 3508 Melsungen Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3422494A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Verfahren und vorrichtung zur spezifischen adsorption von heparin
DE3566409D1 (en) 1984-06-27 1988-12-29 Organon Teknika Bv Binder for low density lipoproteins
FR2571971B1 (fr) * 1984-10-23 1988-12-02 Haas Thierry Dispositif utilisant l'elastine pour abaisser la concentration des constituants lipidiques d'un liquide.
JPS61119271A (ja) 1984-11-13 1986-06-06 鐘淵化学工業株式会社 血液成分処理回路及び血液成分処理方法
EP0184198B1 (en) 1984-12-06 1989-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha A method of preparation of droplets
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4677057A (en) 1985-03-11 1987-06-30 Scripps Clinic And Research Foundation Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
US4675905A (en) * 1985-04-12 1987-06-23 Ampex Corporation Multiple input silent audio switch
US4645512A (en) 1985-05-06 1987-02-24 The Dow Chemical Company Continuous process for removing water-soluble particles from organic liquids
US4895558A (en) * 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
CA1259915A (en) 1985-10-09 1989-09-26 Sailen S. Mookerjea Means to reduce plasma cholesterol
US4832928A (en) * 1985-10-15 1989-05-23 Thermal Science, Inc. Method for producing ammonium polyphosphate
ATE69383T1 (de) * 1985-11-22 1991-11-15 Schweiz Serum & Impfinst Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.
US5080796A (en) 1985-12-19 1992-01-14 The Cleveland Clinic Foundation Thermofiltration of plasma
US4966709A (en) 1985-12-19 1990-10-30 The Cleveland Clinic Foundation Thermofiltration of plasma
US5354262A (en) 1986-02-18 1994-10-11 Boehringer Laboratories Apparatus for removal of insoluble fat from blood of a patient
US5203778A (en) 1986-02-18 1993-04-20 Boehringer Laboratories Process and apparatus for removal of insoluble fat from blood of a patient
US4836034A (en) * 1986-07-15 1989-06-06 Ricoh Company, Ltd. Force sensing apparatus
US5126240A (en) 1986-09-29 1992-06-30 Curtiss Linda K Hybridomas and monoclonal paratopic molecules to apolipoprotein a-i
US4855113A (en) * 1986-10-27 1989-08-08 Pennwalt Corporation Apparatus for removing sulfur from organic polysulfides
US4832034A (en) 1987-04-09 1989-05-23 Pizziconi Vincent B Method and apparatus for withdrawing, collecting and biosensing chemical constituents from complex fluids
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
ATE133423T1 (de) * 1987-05-20 1996-02-15 Rogosin Inst Rekonstituierte hdl-teilchen und ihre verwendung
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
JPH0829316B2 (ja) 1987-10-16 1996-03-27 田辺製薬株式会社 パイロジェンの除去方法
US5055396A (en) 1987-11-03 1991-10-08 Scripps Clinic And Research Foundation Diagnostic methods and systems for quantifying apo ai
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5112956A (en) 1987-12-02 1992-05-12 The Nutrasweet Company Method for extraction of lipids and cholesterol
US4909940A (en) 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
DE8802722U1 (pt) * 1988-03-01 1988-04-14 Industrial Technology Research Institute, Hsinchu, Tw
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5152743A (en) 1988-08-05 1992-10-06 Healthdyne, Inc. Apparatus and method for selective separation of blood cholesterol
US5484396A (en) 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
US5419759A (en) 1988-11-17 1995-05-30 Naficy; Sadeque S. Apparatus and methods for treatment of HIV infections and AIDS
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
US5026479A (en) 1990-02-13 1991-06-25 Union Carbide Industrial Gases Technology Corporation Fluid separation device
DE4018778A1 (de) 1990-06-12 1991-12-19 Braun Melsungen Ag Adsorptionsmaterial zur selektiven entfernung von ldl- oder/und vldl
US5116307A (en) 1990-07-09 1992-05-26 Collins Harvey T Method and system for treatment of AIDS
US5187010A (en) 1990-11-27 1993-02-16 W. R. Grace & Co.-Conn. Membrane having high affinity for low density lipoprotein-cholesterol from whole blood
US5236644A (en) 1990-11-27 1993-08-17 W. R. Grace & Co.-Conn. Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood
US5258149A (en) 1990-11-27 1993-11-02 W. R. Grace & Co.-Conn. Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood
US5418061A (en) 1990-11-27 1995-05-23 W. R. Grace & Co.-Conn. Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
SU1752187A3 (ru) * 1990-12-11 1992-07-30 А.Б.Сигалов Способ делипидировани лиофилизированных липопротеинов высокой плотности из сыворотки крови человека
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US5211850A (en) 1991-07-26 1993-05-18 Research Medical, Inc. Plasma filter sorbent system for removal of components from blood
JP2576744B2 (ja) 1991-11-05 1997-01-29 日揮株式会社 液液接触塔
US5301694A (en) 1991-11-12 1994-04-12 Philip Morris Incorporated Process for isolating plant extract fractions
DE69333329T2 (de) * 1992-01-07 2004-09-09 Mitsubishi Polyester Film Corp. Polyesterfilm
US5919369A (en) 1992-02-06 1999-07-06 Hemocleanse, Inc. Hemofiltration and plasmafiltration devices and methods
WO1993017329A1 (en) 1992-02-24 1993-09-02 Coulter Corporation Suspension media for hematological composition and method for its use
EP0629135B1 (en) 1992-03-02 2000-07-26 Bioeng, Inc. Viral inactivation method
JP2744546B2 (ja) * 1992-04-01 1998-04-28 株式会社栃本天海堂 固体抽出機
US5279540A (en) 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
IL104015A0 (en) 1992-12-07 1993-05-13 Doina International Ltd P Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
US5391143A (en) 1993-03-12 1995-02-21 Kensey Nash Corporation Method and system for effecting weight reduction of living beings
CA2156721C (en) 1993-03-16 1999-06-01 Thomas B. Okarma Removal of selected factors from whole blood or its components
US5401466A (en) 1993-06-01 1995-03-28 Miles Inc. Device for the direct measurement of low density lipoprotein cholesterol
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
PT710126E (pt) 1993-07-30 2004-09-30 Aruba Internat Pty Ltd Sistema de deslipidacao do plasma
ATA159993A (de) 1993-08-10 1995-09-15 Dieter Dr Falkenhagen Anordnung zur elimination von substanzen aus flüssigkeiten
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
EP0882493A3 (en) 1994-06-22 1999-06-30 Fls Miljo A/S Mass transfer method
US5962322A (en) 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US5637224A (en) 1994-09-14 1997-06-10 New Jersey Institute Of Technology Hollow fiber contained liquid membrane pervaporation for removal of volatile organic compounds from aqueous solutions
DE4435612A1 (de) 1994-10-05 1996-04-11 Braun Melsungen Ag Verfahren zur simultanen Entfernung von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus einer wäßrigen Flüssigkeit
AUPN030794A0 (en) * 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
US5634893A (en) 1995-04-24 1997-06-03 Haemonetics Corporation Autotransfusion apparatus
JP3595608B2 (ja) * 1995-05-30 2004-12-02 アネルバ株式会社 真空処理装置、真空処理装置における真空容器内面堆積膜除去方法及び真空処理装置における真空容器内面膜堆積均一化方法
US5719194A (en) 1995-08-22 1998-02-17 Ausimont S.P.A. Prevention and treatment of topical viral infections with perfluoropolyethers or compositions thereof
US5911698A (en) 1995-12-22 1999-06-15 Aruba International Pty. Ltd. Treatment for cardiovascular and related diseases
AU2212897A (en) 1996-03-08 1997-09-22 Baxter Research Medical, Inc. Selective membrane/sorption techniques for salvaging blood
US6171373B1 (en) * 1996-04-23 2001-01-09 Applied Ceramics, Inc. Adsorptive monolith including activated carbon, method for making said monolith, and method for adsorbing chemical agents from fluid streams
WO1998001464A1 (en) * 1996-07-10 1998-01-15 American National Red Cross Methods for the selective separation of organic components from biological fluids
AU6059898A (en) 1996-09-05 1998-03-26 Uab Research Foundation, The Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
US5707673A (en) 1996-10-04 1998-01-13 Prewell Industries, L.L.C. Process for extracting lipids and organics from animal and plant matter or organics-containing waste streams
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6605588B1 (en) * 1996-11-27 2003-08-12 Boston Heart Foundation, Inc. Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
TW318283B (en) * 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6022333A (en) * 1997-05-01 2000-02-08 S.L.I.M. Tech, Ltd. Method and system for removing materials from lymphatic and other fluids
US6337368B1 (en) * 1997-06-03 2002-01-08 Kaneka Corporation Lipoprotein adsorbent and lipoprotein adsorber made with the use of the same
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US5980478A (en) 1997-10-10 1999-11-09 Transvivo, Inc. Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration
CN1070380C (zh) * 1997-12-30 2001-09-05 长春市中心血站 高密度脂蛋白制剂的生产方法
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
US20020055529A1 (en) * 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
EP1140252A2 (en) * 1998-12-29 2001-10-10 Occulogix Corporation Rheological treatment methods and related apheresis systems
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AUPQ486699A0 (en) 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
AU2001278084A1 (en) 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
IL155215A0 (en) 2000-10-11 2003-11-23 Esperion Therapeutics Inc Ether compounds and compositions for cholesterol management and related uses
CA2437480A1 (en) 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid .beta. precursor disorder
US6706008B2 (en) * 2001-03-06 2004-03-16 Baxter International Inc. Automated system and method for withdrawing compounds from blood
US20030104350A1 (en) * 2001-06-25 2003-06-05 Bomberger David C. Systems and methods using a solvent for the removal of lipids from fluids
WO2004017946A1 (en) * 2002-08-26 2004-03-04 Lipid Sciences, Inc. Treating alzheimers using delipidated protein particles
EP1641421B1 (en) * 2003-07-03 2018-12-26 HDL Therapeutics, Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content

Also Published As

Publication number Publication date
JP2007527387A (ja) 2007-09-27
US20080230465A1 (en) 2008-09-25
EP2368565A1 (en) 2011-09-28
CA2531227A1 (en) 2005-02-10
EP1641421A2 (en) 2006-04-05
DK1641421T3 (en) 2019-03-11
US20080234621A1 (en) 2008-09-25
EP2368565B1 (en) 2015-06-24
US20050090444A1 (en) 2005-04-28
AU2004260632A1 (en) 2005-02-10
ES2547547T3 (es) 2015-10-07
EP1641421B1 (en) 2018-12-26
PT1641421T (pt) 2019-03-27
US20080214438A1 (en) 2008-09-04
ES2715496T3 (es) 2019-06-04
DK2368565T3 (en) 2015-09-28
US8048015B2 (en) 2011-11-01
WO2005011620A2 (en) 2005-02-10
WO2005011620A3 (en) 2006-05-18
US7361739B2 (en) 2008-04-22
EP1641421A4 (en) 2006-10-18
US7375191B2 (en) 2008-05-20
US20050004004A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
PT2368565E (pt) Enriquecimento de lipoproteínas pré-beta de alta densidade
HUE038345T2 (hu) Mágneses dúsítási eljárás
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
EP1723414A4 (en) NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
GB2407293B (en) Methods of making laryngeal masks
HK1096398A1 (en) Method for the manufacture of thip thip
DK1572950T3 (da) Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
EP1648223A4 (en) NPC1L1 (NPC3) AND METHOD OF USE THEREOF
GB0304555D0 (en) Compounds and methods of manufacture
GB0423392D0 (en) Methods of making laryngeal masks
EP1686990A4 (en) 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS: METHODS OF PREPARATION AND USE
FR2860995B1 (fr) Separateur magnetique
GB0400308D0 (en) Magnetic separators
AU2003300054A8 (en) Digital guitar
EP1725868A4 (en) METHODS OF USING ATIII VARIANTS WITH HIGH AFFINITY
TW571780U (en) Improved structure of stepper
TW568002U (en) Improved structure for core material
GB2433671B (en) Speaker Structure
TW556951U (en) Structure improvement of fuse stage
TW576247U (en) An improved structure for badminton
TW590306U (en) Adjusting structure for loose-and-tight of cymbals
GB0307280D0 (en) Screening of compounds
AU152460S (en) Set of components for construction games
TW592372U (en) Improved structure of guitar stand